## **REMARKS**

## Formal Matters

Claims 8-25 are pending.

Claims 8-25 were examined and rejected. No claims were allowed.

Claims 8 and 21-23 are amended. The amendments were made solely in the interest of expediting prosecution, and are not to be construed as an acquiescence to any objection or rejection of any claim. Support for the amendments to the claims is found in the claims as originally filed, and throughout the specification, in particular at the following exemplary locations: page 15, lines 14-20 and page 8, lines 7-8.

No new matter is added by these amendments.

Applicants respectfully request reconsideration of the application in view of the amendments and remarks made herein.

## **Interview summary**

The Applicants wish to express their gratitude to Examiner Brusca for the interview on February 8, 2005, with Applicants' representative James Keddie.

The enablement rejection was discussed.

Examiner Brusca agreed that the enablement rejection would be addressed by amending the claims to recite.... "an interaction between a test peptide and a cellular *component*".

Such an amendment is made herein. In view of this amendment, the Applicants request withdrawal of this rejection. A Notice of Allowance is respectfully requested.

## Rejection of claims under 35 U.S.C. § 112, first paragraph (enablement)

Claims 8-20 are rejected under U.S.C. § 112, first paragraph, as failing to comply with the enablement requirement of U.S.C. § 112, first paragraph.

Without any intention to acquiesce to the correctness of this rejection and solely to expedite prosecution, the claims have been amended to recite "an interaction between a test peptide and a cellular *component*".

USSN: 10/057,467ATTY. DOCKET NO: RIGL-005CON

In view of the agreement made in the aforementioned interview, this Applicants respectfully request withdrawal of this rejection.

USSN: 10/057,467

ATTY. DOCKET NO: RIGL-005CON

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number RIGL-005CON.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: Feb 14, 2005

James S. Keddie, Ph.D. Registration No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Circle, Suite 200

East Palo Alto, California 94303

Telephone: (650) 327-3400

Facsimile: (650) 327-3231

F:\DOCUMENT\RIGL (Rigel)\005CON\response to OA of May 18, 2004 -supplementa .doc